You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 150 No. 5, May 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Isolated Systolic Hypertension With Labetalol in the Elderly

Thomas D. Giles, MD; Michael Weber, MD; David W. Bartels, PharmD; Harold M. Silberman, MD; Lawrence P. Gilderman, DO; James F. Burns, MD

Arch Intern Med. 1990;150(5):974-976.


Abstract

• Antihypertensive therapy with labetalol was evaluated in a prospective, randomized, multicenter, double-blind study of 133 elderly patients with isolated systolic hypertension (standing systolic blood pressure [BP] ≥160 mm Hg; diastolic BP 95 mm Hg). Following a placebo-washout period, patients received either labetalol (n 70) or placebo (n = 63), which was titrated as necessary from 100 to 400 mg twice a day over a 6-week period. Once the BP was controlled (standing systolic BP <160 mm Hg, and 10-mm10-mm Hg decrease from baseline) or the maximum dosage had been given, patients continued receiving the same regimen until the end of the titration period and throughout a 4-week maintenance period. Blood pressure was controlled in 57 (81%) of 70 of the labetalol-treated patients (86% receiving ≥200 mg twice a day) compared with 34 (54%) of 63 of the placebo-treated patients. Throughout the active treatment periods, BP was significantly lower in patients treated with labetalol compared with those taking placebo; mean standing systolic BP decreased 26 mm Hg in the labetalol group vs 9 mm Hg in the placebo group. Side effects were generally mild, and the dropout rates due to adverse experiences were similar between treatment groups (14% in the labetalol group vs 10% in the placebo group). In summary, labetalol can effectively lower systolic BP in the elderly without causing adverse orthostatic changes.

(Arch Intern Med. 1990;150:974-976)



Author Affiliations

From the Tulane University School of Medicine, New Orleans, La (Dr Giles); Veterans Affairs Center, Long Beach, Calif (Dr Weber); University of Illinois College of Medicine at Rockford (Dr Bartels); and the Veterans Affairs Medical Center, Washington, DC (Dr Burris). Drs Silberman and Gilderman are in private practice in Coral Gables and Pembroke Pines, Fla, respectively.


Footnotes

Accepted for publication December 29,1989.

Reprint requests to the Cardiovascular Research Laboratory, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112 (Dr Giles).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Perspectives on Isolated Systolic Hypertension in Elderly Patients
Vardan and Mookherjee
Arch Fam Med 2000;9:319-323.
ABSTRACT | FULL TEXT  

LABETALOL FOR SYSTOLIC HYPERTENSION IN THE ELDERLY
JWatch General 1990;1990:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.